RecruitingNCT07201025
Imaging Assessments of ARPKD Kidney Disease Progression
Studying Autosomal recessive polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Cleveland Clinic
- Principal Investigator
- Katherine M Dell, MD, CRNPThe Cleveland Clinic
- Enrollment
- 60 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2024 – 2029
Study locations (2)
- Cleveland Clinic, Cleveland, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07201025 on ClinicalTrials.govOther trials for Autosomal recessive polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06601829Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University HospitalSohag University
- RECRUITINGPHASE3NCT04782258A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)Otsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNCT01401998ARPKD Database StudyChildren's Hospital of Philadelphia
See all trials for Autosomal recessive polycystic kidney disease →